(Q43635299)

25 November 2017

Comparative evaluation of fecal fat excretion induced by orlistat and chitosan (English)

1 reference

25 November 2017

0 references

Guerciolini R

1

1 reference

25 November 2017

Radu-Radulescu L

2

1 reference

25 November 2017

Boldrin M

3

1 reference

25 November 2017

Dallas J

4

1 reference

25 November 2017

Moore R

5

1 reference

25 November 2017

1 June 2001

1 reference

25 November 2017

1 reference

25 November 2017

9

1 reference

25 November 2017

6

1 reference

25 November 2017

364-367

1 reference

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

25 November 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2001.47

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2001.47

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2001.47

Solubility and structure of N-carboxymethylchitosan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2001.47

Randomized, double-blind trial of chitosan for body weight reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2001.47

Dietary chitosan inhibits hypercholesterolaemia and atherogenesis in the apolipoprotein E-deficient mouse model of atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2001.47

A descriptive study of weight loss maintenance: 6 and 15 year follow-up of initially overweight adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2001.47

Dietary fat intake does affect obesity!

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2001.47

Orlistat in the long-term treatment of obesity in primary care settings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2001.47

Mechanism for the inhibition of fat digestion by chitosan and for the synergistic effect of ascorbate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2001.47

Decrease in serum LDL cholesterol with microcrystalline chitosan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2001.47

Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2001.47

A novel use of chitosan as a hypocholesterolemic agent in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2001.47

31 March 2020

Identifiers

DOI

10.1038/OBY.2001.47

1 reference

25 November 2017

1 reference